Piper Sandler lowered the firm’s price target on Vicarious Surgical (RBOT) to $7 from $8.50 and keeps a Neutral rating on the shares following quarterly results. Most notably, the company removed its goal for first clinical use by year-end and instead is focused on completing a fully integrated, production-equivalent system enabling design lock and initiating full system V&V, the firm says.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RBOT:
- Vicarious Surgical Reports Improved Q2 Financials and Leadership Change
- Strategic Leadership Change and Prioritization Boost Vicarious Surgical’s Growth Prospects
- Vicarious Surgical reports Q2 EPS ($2.23), consensus ($2.50)
- Vicarious Surgical anticipates FY25 cash burn of about $50M
- RBOT Upcoming Earnings Report: What to Expect?